Sign In
Buy RCEL
$4.16
-0.0300 (-0.716%)
At Close: Jun 03, 2026
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
05:05pm, Thursday, 19'th Dec 2024
New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical's addressable market in burns VALENCIA, Calif., Dec. 1
AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:08pm, Wednesday, 18'th Dec 2024
VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana
AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
04:02pm, Monday, 25'th Nov 2024
VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana
AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand
04:03pm, Tuesday, 12'th Nov 2024
VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in commercial-stage regenerative medicine and pioneering devices for wound care
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
06:39am, Saturday, 09'th Nov 2024
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Office
AVITA Medical to Host Investor Webinar Briefing
09:00am, Friday, 08'th Nov 2024
VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana
AVITA Medical Reports Third Quarter Financial Results
04:03pm, Thursday, 07'th Nov 2024
VALENCIA, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana
AVITA Medical to Announce Third Quarter 2024 Financial Results
05:15pm, Thursday, 10'th Oct 2024
AVITA Medical announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on November 7, 2024.
AVITA Medical Headed For Its Most Important Report, I'm Extremely Bullish
01:07pm, Wednesday, 02'nd Oct 2024
AVITA Medical's RECELL GO offers superior wound healing with less donor skin required, reducing scarring and infection risk. It has no direct competition. RECELL GO streamlines the skin grafting proce
AVITA Medical to Present at 2024 Cantor Global Healthcare Conference
04:05pm, Thursday, 12'th Sep 2024
VALENCIA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care man
AVITA Medical to Participate in Lake Street's 8th Annual Best Ideas Growth (BIG8) Conference
04:03pm, Tuesday, 10'th Sep 2024
VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care man
AVITA Medical: New Products, Same Old Cash Burn (Rating Downgrade)
04:39pm, Tuesday, 27'th Aug 2024
RECELL GO's launch increased SG&A expenses, contributing to AVITA Medical, Inc.'s higher net losses in Q2 2024. Despite lowering its 2024 revenue guidance, AVITA Medical still anticipates significant
AVITA Medical, Inc. (RCEL) Q2 2024 Earnings Call Transcript
06:01am, Friday, 09'th Aug 2024
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer
AVITA Medical to Host Investor Webinar Briefing
07:00pm, Thursday, 08'th Aug 2024
VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana
AVITA Medical Reports Second Quarter Financial Results
04:04pm, Thursday, 08'th Aug 2024
AVITA Medical today reported second-quarter commercial revenue of $15.1 million, reflecting growth of over 29% over the same period in the prior year.
